Vassiliki Papadimitrakopoulou, MD, from the University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.
Roy S. Herbst, MD, PhD, from Yale-New Haven in Connecticut, discusses the benefit of treating lung cancer with immunotherapy.
The Cancer Genome Atlas (TCGA) began in 2006, with a total investment of $100 million from the National Cancer Institute and the National Human Genome Research Institute for a 3-year pilot period.
Drs. Grace Dy and Hongbin Chen Discuss Systemic Treatment for Metastatic, Non-Small Cell Lung Cancer (NSCLC)
Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Immunotherapies have shown great promise in the treatment of advanced cancers, including metastatic melanoma and non-small cell lung cancers (NSCLC)
Oncogenic driver mutations have been detected in over 60% of the non-small cell lung cancer (NSCLC) tumor samples surveyed by the Lung Cancer Mutation Consortium (LCMC).
JTT Articles
Targeting Radiotherapy in the Liver: SIR-Spheres®
HPV Test With Genotyping Supplants Pap Test
Management of Hepatocellular Cancer
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.